1. Home
  2. RGC vs GBIO Comparison

RGC vs GBIO Comparison

Compare RGC & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regencell Bioscience Holdings Limited

RGC

Regencell Bioscience Holdings Limited

HOLD

Current Price

$18.85

Market Cap

8.4B

Sector

Health Care

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.48

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGC
GBIO
Founded
2014
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
36.3M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
RGC
GBIO
Price
$18.85
$5.48
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
217.0K
51.7K
Earning Date
10-24-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$3.00
52 Week High
$83.60
$12.50

Technical Indicators

Market Signals
Indicator
RGC
GBIO
Relative Strength Index (RSI) 69.39 53.08
Support Level $16.30 $5.20
Resistance Level $18.10 $5.54
Average True Range (ATR) 1.70 0.25
MACD 0.45 0.04
Stochastic Oscillator 100.00 69.49

Price Performance

Historical Comparison
RGC
GBIO

About RGC Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: